Table 2 Clinical characteristics of study participants during MDR-TB treatment at St.Peter’s Specialized Hospital and ALERT center, Addis Ababa, Ethiopia
Clinical characteristics | N(%) | |
|---|---|---|
Case registration | New case | 77 (8.3) |
Relapse | 124 (13.3) | |
After failure of first treatment | 213 (22.9) | |
After failure of re-treatment | 442 (47.5) | |
Treatment after being lost to follow- up | 4 (0.4) | |
Transfer -in | 2 (0.2) | |
Other | 11 (1.2) | |
TB treatment in the past | Yes | 788 (84.6) |
No | 63 (6.8) | |
Unknown | 27 (2.9) | |
Treatment taken for past TB | First-line drugs | 792 (85.1) |
Second- line drugs | 25 (2.7) | |
Both first and second line drugs | 4 (0.4) | |
Second- line past injectable treatment | Kanamycin | 1 (0.1) |
Amikacin | 6 (0.6) | |
Capreomycin | 17 (1.8) | |
Streptomycin | 33 (3.5) | |
Anatomical site TB | Pulmonary | 817 (87.8) |
Extrapulmonary | 59 (6.3) | |
MTB detection | Bacteriologically confirmed MDR-TB | 850 (91.3) |
Clinically diagnosed MDR-TB | 27 (2.9) | |
NA | 2 (0.2) | |
MTB confirmation | GeneXpert MTB/RIF positive | 347 (37.5) |
Culture | 234 (25.1) | |
Line probe assay | 214 (23.0) | |
Sputum smear positive | 29 (3.1) | |
Resistance /Sensitivity testing | GeneXpert MTB/RIF | 356 (38.2) |
Line probe assay | 232 (24.9) | |
Phenotypic drug susceptibility testing | 242 (26.0) | |
NA + other | 42 (4.7) | |
HIV status | HIV positive MDR-TB patients | 171 (18.4) |
HIV negative MDR-TB patients | 685 (73.6) | |
HIV status unknown MDR-TB patients | 23 (2.4) | |
Pattern of resistance | Isoniazid and rifampicin resistance | 341 (40.1) |
GeneXpertMTB/RIF rifampicin only resistance | 260 (30.6) | |
Rifampicin resistance with isoniazid susceptibility | 38 (4.5) | |
Isoniazid, rifampicin, ethambutol, streptomycin, resistance | 132 (15.5) | |
Isoniazid, rifampicin and streptomycin resistance | 1 (0.1) | |
Others | 94 (10.1) | |